Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 7.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,240 shares of the biopharmaceutical company’s stock after selling 342 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Halozyme Therapeutics were worth $204,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth approximately $29,000. GAMMA Investing LLC lifted its stake in shares of Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 350 shares during the last quarter. Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter worth $57,000. FSC Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth about $65,000. Finally, CWM LLC increased its position in shares of Halozyme Therapeutics by 77.5% during the 3rd quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 668 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $58.61 on Friday. Halozyme Therapeutics, Inc. has a 52 week low of $34.70 and a 52 week high of $65.53. The company has a fifty day simple moving average of $52.09 and a two-hundred day simple moving average of $54.45. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The company has a market cap of $7.46 billion, a price-to-earnings ratio of 19.41, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

HALO has been the topic of a number of recent analyst reports. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, February 4th. JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company cut their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $60.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.